Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) Director Charles Cliff Duncan bought 3,447 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $13,167.54. Following the transaction, the director directly owned 102,898 shares in the company, valued at approximately $393,070.36. This trade represents a 3.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Charles Cliff Duncan also recently made the following trade(s):
- On Thursday, November 5th, Charles Cliff Duncan acquired 5,803 shares of Vanda Pharmaceuticals stock. The shares were bought at an average price of $3.80 per share, with a total value of $22,051.40.
- On Tuesday, November 3rd, Charles Cliff Duncan bought 750 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $3.80 per share, for a total transaction of $2,850.00.
Vanda Pharmaceuticals Stock Down 7.5%
Shares of NASDAQ:VNDA traded down $0.29 during trading on Thursday, reaching $3.59. The stock had a trading volume of 1,239,112 shares, compared to its average volume of 1,499,630. Vanda Pharmaceuticals Inc. has a one year low of $3.57 and a one year high of $9.94. The company has a market capitalization of $217.09 million, a P/E ratio of -0.78 and a beta of 0.74. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $4.70 and its 200 day simple moving average is $6.16.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. The firm had revenue of $69.81 million during the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. As a group, research analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC lifted its position in Vanda Pharmaceuticals by 8.8% during the 1st quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 3,144 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $29,000. Legal & General Group Plc acquired a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $34,000. Allworth Financial LP purchased a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $43,000. Finally, SG Americas Securities LLC boosted its position in Vanda Pharmaceuticals by 94.7% in the first quarter. SG Americas Securities LLC now owns 21,042 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 10,235 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.
Key Stories Impacting Vanda Pharmaceuticals
Here are the key news stories impacting Vanda Pharmaceuticals this week:
- Positive Sentiment: Director Charles Cliff Duncan bought shares on November 3, 4 and 5, investing about $38,000 in total and increasing his stake. The purchases may signal confidence in Vanda’s prospects. SEC filing
- Neutral Sentiment: HC Wainwright maintained its “Buy” rating and raised its FY2026 loss estimate to $2.45 per share from $3.03, while improving its Q4 2026 estimate. That outlook is partly offset by a wider projected FY2027 loss of $1.02 per share, versus $0.94 previously.
- Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for Q2, Q3 and Q4 2027, suggesting weaker earnings expectations for much of that year. VNDA is also trading near its 12-month low and below its 50- and 200-day moving averages, reflecting continued share-price weakness.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. Zacks Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, Oppenheimer initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.50.
Get Our Latest Stock Analysis on Vanda Pharmaceuticals
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.
Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.
Read More
- Five stocks we like better than Vanda Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
